Current Understanding on Why Ovarian Cancer Is Resistant to Immune Checkpoint Inhibitors
International Journal of Molecular Sciences · 29.06.2023 · 24 (13) · 10859
DOI: 10.3390/ijms241310859 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 29.06.2023. Verfasst von Anna Pawłowska und 5 weiteren Autor:innen. Beteiligte Einrichtung: Independent Laboratory of Cancer Diagnostics and Immunology, Department of Oncological Gynaecology and Gynaecology, Faculty of Medicine, Medical Univ…. Hauptthemen laut MEDLINE: Immune Checkpoint Inhibitors, Ovarian Neoplasms. Die Arbeit wurde bisher 70-mal zitiert (Crossref) und nennt 232 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: This work was supported by the Medical University of Lublin, grant number DS124, and in part by National Science Centre, Poland, Preludium grant number 2021/41…, Medical University of Lublin, National Science Centre, Poland.
Abstract (Originalsprache)
The standard treatment of ovarian cancer (OC) patients, including debulking surgery and first-line chemotherapy, is unsatisfactory because of recurrent episodes in the majority (~70%) of patients with advanced OC. Clinical trials have shown only a modest (10–15%) response of OC individuals to treatment based on immune checkpoint inhibitors (ICIs). The resistance of OC to therapy is caused by various factors, including OC heterogeneity, low density of tumor-infiltrating lymphocytes (TILs), non-cellular and cellular interactions in the tumor microenvironment (TME), as well as a network of microRNA regulating immune checkpoint pathways. Moreover, ICIs are the most efficient in tumors that are marked by high microsatellite instability and high tumor mutation burden, which is rare among OC patients. The great challenge in ICI implementation is connected with distinguishing hyper-, pseudo-, and real progression of the disease. The understanding of the immunological, molecular, and genetic mechanisms of OC resistance is crucial to selecting the group of OC individuals in whom personalized treatment would be beneficial. In this review, we summarize current knowledge about the selected factors inducing OC resistance and discuss the future directions of ICI-based immunotherapy development for OC patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Independent Laboratory of Cancer Diagnostics and Immunology, Department of Oncological Gynaecology and Gynaecology, Faculty of Medicine, Medical University of Lublin, Chodźki 1, 20-093 Lublin, Poland.
- Students' Scientific Association, Independent Laboratory of Cancer Diagnostics and Immunology, Medical University of Lublin, Chodźki 1, 20-093 Lublin, Poland.
- Institute of Medical Sciences, Department of Biology and Genetics, Faculty of Medicine, University of Opole, Oleska 48, 45-052 Opole, Poland.
ORCID-Profile: Anna Pawłowska, Anna Rekowska, Weronika Kuryło, Jan Kotarski, Iwona Wertel
Förderung
- This work was supported by the Medical University of Lublin, grant number DS124, and in part by National Science Centre, Poland, Preludium grant number 2021/41…
- Medical University of Lublin
- National Science Centre, Poland
Zitieren
APA
Pawłowska, A., Rekowska, A., Kuryło, W., Pańczyszyn, A., Kotarski, J., & Wertel, I. (2023). Current Understanding on Why Ovarian Cancer Is Resistant to Immune Checkpoint Inhibitors. International Journal of Molecular Sciences, 24(13), 10859. https://doi.org/10.3390/ijms241310859
Vancouver
Pawłowska A, Rekowska A, Kuryło W, Pańczyszyn A, Kotarski J, Wertel I. Current Understanding on Why Ovarian Cancer Is Resistant to Immune Checkpoint Inhibitors. International Journal of Molecular Sciences. 2023;24(13):10859. doi:10.3390/ijms241310859
BibTeX
@article{Pawowska2023,
author = {Pawłowska, Anna and Rekowska, Anna and Kuryło, Weronika and Pańczyszyn, Anna and Kotarski, Jan and Wertel, Iwona},
title = {Current Understanding on Why Ovarian Cancer Is Resistant to Immune Checkpoint Inhibitors},
journal = {International Journal of Molecular Sciences},
year = {2023},
volume = {24},
number = {13},
pages = {10859},
doi = {10.3390/ijms241310859}
}
EUVIMED